A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTor inhibitor GDC-0980 administered QW

被引：1
|
作者：
Wagner, A. J. [1 ]
Jayson, G. C. [2 ]
Gomez-Roca, C. [3 ]
Zee, Y. K. [2 ]
Morgan, J. A. [1 ]
Yan, Y. [4 ]
Ware, J. [4 ]
Mazina, K. E. [4 ]
Lauchle, J. [4 ]
Soria, J. C. [3 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Inst Cancerol Gustave Roussy, Villejuif, France
[4] Genentech Inc, GRED, San Francisco, CA 94080 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72096-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：123 / 124
页数：2
相关论文
共 50 条
  • [21] Combination Therapy of the Novel PI3K Inhibitor GDC-0941 and Dual PI3K/mTOR Inhibitor GDC-0980 with Trastuzumab-DM1 Antibody Drug Conjugate Enhances Anti-Tumor Activity in Preclinical Breast Cancer Models In Vitro and In Vivo
    Sampath, D.
    Fields, C.
    Li, G.
    Prior, W. W.
    Parsons, K.
    Friedman, L. S.
    Lewis-Phillips, G. D.
    CANCER RESEARCH, 2010, 70
  • [22] Evaluation of tolerability and anti-tumor activity of GDC-0980, an oral PI3K/mTOR inhibitor, administered to patients with-advanced solid tumors or non-Hodgkin's lymphoma (NHL)
    Dolly, S.
    Bendell, J. C.
    Kindler, H. L.
    Lauchle, J. O.
    Krug, L. M.
    Seiwert, T. Y.
    Burris, H. A.
    DeBono, J. S.
    Wagner, A. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S162 - S162
  • [23] Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets
    Al-Ghabkari, Abdulhameed
    Perinpanayagam, Maneka A.
    Narendran, Aru
    CURRENT CANCER DRUG TARGETS, 2019, 19 (10) : 828 - 837
  • [24] Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer
    Sutherlin, Daniel P.
    Bao, Linda
    Berry, Megan
    Castanedo, Georgette
    Chuckowree, Irina
    Dotson, Jenna
    Folks, Adrian
    Friedman, Lori
    Goldsmith, Richard
    Gunzner, Janet
    Heffron, Timothy
    Lesnick, John
    Lewis, Cristina
    Mathieu, Simon
    Murray, Jeremy
    Nonomiya, Jim
    Pang, Jodie
    Pegg, Niel
    Prior, Wei Wei
    Rouge, Lionel
    Salphati, Laurent
    Sampath, Deepak
    Tian, Qingping
    Tsui, Vickie
    Wan, Nan Chi
    Wang, Shumei
    Wei, BinQing
    Wiesmann, Christian
    Wu, Ping
    Zhu, Bing-Yan
    Olivero, Alan
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (21) : 7579 - 7587
  • [25] GDC-0980, a novel PI3K/mTOR kinase inhibitor, is effective in HER2 positive gastric cancer (GC) cell lines resistant to Trastuzumab
    Ventriglia, J.
    Laterza, M. M.
    Capasso, A.
    Belli, V.
    Savastano, B.
    Petrillo, A.
    Tirino, G.
    Pompella, L.
    Diana, A.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer
    Spoerke, Jill M.
    Makker, Vicky
    Aghajanian, Carol
    Thomas, Powles
    Motzer, Robert J.
    Lauchle, Jennifer O.
    Parmar, Hema
    Gilbert, Houston
    Lin, Wei
    O'Keeffe, Bridget
    Byrtek, Michelle
    Koeppen, Hartmut
    Wang, Yulei
    Lu, Shan
    Huw, Ling-Yuh
    Hampton, Garret M.
    Lackner, Mark R.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [27] Phase Ib study of oral dual-PI3K/mTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6+bevacizumab in patients with advanced solid tumors and colorectal cancer
    Roseri, L.
    Goldman, J.
    Hubbard, J. M.
    Roos, M.
    Capdevila, J.
    Maynes, J.
    Lin, W.
    O'Keeffe, B.
    Lackner, M.
    Spoerke, J.
    Ware, J.
    Arnieri, B.
    Freas, E.
    Leong, S.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 122 - 123
  • [28] A PHASE 1B STUDY TO EVALUATE THE SAFETY AND PHARMACOLOGY OF THE DUAL PI3K-MTOR INHIBITOR GDC-0980 IN COMBINATION WITH A FLUOROPYRIMIDINE, OXALIPLATIN, AND BEVACIZUMAB (BEV) IN PATIENTS WITH ADVANCED SOLID TUMORS
    Rosen, L. S.
    Goldman, J.
    Stewart, S.
    Hubbard, J. M.
    Roos, M.
    Lin, W.
    Shankar, G.
    Capdevila, J.
    Freas, E.
    Leong, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 157 - 157
  • [29] GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway
    Jang, Dong Kee
    Lee, Yu Geon
    Chae, Young Chan
    Lee, Jun Kyu
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    Ryu, Ji Kon
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 529 (04) : 1242 - 1248
  • [30] GDC-0980, a dual PI3K/mTOR inhibitor, selectively inhibits NF2 mutant malignant mesothelioma (MM) cells and inhibits TOR signaling without activating Akt or ERK
    Zauderer, Marjorie G.
    Moulik, Kamalika
    Cooper, Jonathan
    Krug, Lee M.
    Giancotti, Filippo
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
12345